Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.

@article{Branson2002RoleON,
  title={Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.},
  author={Katharine Branson and Rajesh K. Chopra and Panagiotis D. Kottaridis and Grant McQuaker and Anne Parker and Stephen A. Schey and Ronjon K Chakraverty and Charles G. Craddock and Donald W. Milligan and Ruth Pettengell and Judith C. W. Marsh and David Christopher Linch and Anthony H. Goldstone and Catherine D. Williams and Stephen Mackinnon},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 19},
  pages={4022-31}
}
PURPOSE Conventional allogeneic stem-cell transplantation (SCT) after a prior failed autograft is associated with a transplant-related mortality rate of 50% to 80%. The aim of the current study was to evaluate the safety and efficacy of sibling, HLA-matched, nonmyeloablative allogeneic SCT with donor lymphocyte infusion (DLI) in patients with lymphoid malignancy after failure of autologous SCT. PATIENTS AND METHODS A total of 38 patients with refractory, progressive, or relapsed disease after… CONTINUE READING